Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 4921 results found since Jan 2013.
Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments
This study reviewed the recent trends in the epidemiological characteristics of HBV in the Gambia. The researchers conducted an online literature search for primary studies on HBV prevalence published in the past two decades from Jan 1992 to Feb 2022 inclusive on Google Scholar, PubMed, and Scopus. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness, and methodological coherence. We found that HBV infection prevalence is above 8% in The Gambia. Moreover, HBV is the most common cause of hepatocellular carcinoma (HCC) in Gambia. Liver cirrhosis and HCC hav...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Muhammed Camara Marcarious M Tantuoyir SeyedAhmad SeyedAlinaghi Fereshteh Ghiasvand Zahra Ahmadinejad Source Type: research
Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021
CONCLUSION: The coverage level and service quality of routine immunization in Beijing were relatively high. However, as influenced by COVID-19 epidemics, both on-time and in-time vaccination rates decreased significantly, except for BCG and HepB. Under the background of COVID-19 pandemic, the keys to maintain high level of vaccination coverage include flexible immunization service time to ensure the guardians bringing their children for vaccination timely, and more attention from providers to the doses after children's first birthday.PMID:37709591 | DOI:10.1016/j.vaccine.2023.08.015
Source: Vaccine - September 14, 2023 Category: Allergy & Immunology Authors: Wen-Yan Ji Dong-Lei Liu Rui Yu Liang Miao Qian-Li Yuan Luo-Dan Suo Jian-Ping Yu Source Type: research
Autoimmune hepatitis following mRNA COVID-19 vaccine
Therapie. 2023 Aug 29:S0040-5957(23)00109-9. doi: 10.1016/j.therap.2022.12.014. Online ahead of print.NO ABSTRACTPMID:37704459 | DOI:10.1016/j.therap.2022.12.014
Source: Therapie - September 13, 2023 Category: Psychiatry & Psychology Authors: Ahmed Zaiem Khouloud Ferchichi Ghozlane Lakhoua Widd Kaabi Imen Aouinti Sana Rebii Debbiche Sarrah Kastalli Lamia Kallel Ons Charfi Sihem El Aidli Source Type: research
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
Eliminating hepatitis B vaccination disparities for West African immigrants
Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.08.058. Online ahead of print.ABSTRACTBACKGROUND: Hepatitis B virus (HBV) infection is endemic in West Africa. There has been a significant increase in the Bronx West African (WA) community. To achieve HBV elimination, vaccination of non-immune individuals is important. Unfortunately, vaccine uptake in immigrant populations is at this time very limited.METHODS: An educational program was conducted by medical providers of WA origin in collaboration with local faith-based organizations, after which free HBV screening was offered. Non-immune individuals we...
Source: Vaccine - September 5, 2023 Category: Allergy & Immunology Authors: Jessie A Birnbaum Daniel Guttman Mugdha Parulekar Fatima Omarufilo Emmanuel U Emeasoba Julie Nguyen Oluwadara Tokunboh Jared Coe Matthew J Akiyama Samuel H Sigal Source Type: research
Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study
CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
